Table 1 Clinical features of myeloid patients with COVID-19 infection.

From: Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality

 

All (n = 16)

Alive (n = 11)

Dead (n = 5)

p value

Clinical features at baseline

Median age, years (range)

77 (27–94)

77 (47–89)

85 (64–94)

0.15

M/F

10/6

5/6

5/0

0.04

LR-MDS, n (%)

4 (25)

3 (28)

1 (20)

0.59

MPN, n (%)

5 (31)

4 (36.4)

1 (20)

0.59

MDS/MPN, n (%)

3 (19)

2 (18)

1 (20)

0.69

HR-MDS/AML, n (%)

4 (25)

2 (18)

2 (40)

0.4

Comorbidities

CCI, median (range)

1 (0–6)

0 (0–4)

3 (1–6)

0.03

Hypertension, n (%)

9 (56)

5 (45)

4 (80)

0.18

Other cardiovascular, n (%)

6 (37)

4 (36)

2 (40)

0.56

Autoimmune, n (%)

2 (12.5)

2 (18)

0 (0)

0.42

Thrombosis, n (%)

5 (31)

3 (27)

2 (40)

0.4

Metabolic, n (%)

7 (44)

3 (27)

4 (80)

0.1

Neurologic, n (%)

3 (19)

2 (18)

1 (20)

0.75

Nephrologic, n (%)

2 (12.5)

0 (0)

2 (40)

0.09

Respiratory, n (%)

1 (6)

1 (9)

0 (0)

0.66

Solid tumour, n (%)

3 (19)

2 (18)

1 (20)

0.75

Hepatic, n (%)

1 (6)

0 (0)

1 (20)

0.33

Haematologic treatment

Follow up

5 (31)

5 (45)

0 (0)

0.08

TKI

2 (12.5)

1 (9)

1 (20)

0.57

BSC

5 (31)

1 (9)

4 (80)

0.003

Steroids

3 (19)

3 (27)

0 (0)

0.5

ESA

1 (6)

1 (9)

0 (0)

0.66

Other medications

Anti-hypertensive, n (%)

8 (50)

5 (45)

3 (60)

0.42

ACEi/ARBs, n (%)

3 (19)

2 (18)

1 (20)

0.75

Anti-coagulant, n (%)

2 (12.5)

1 (9)

1 (20)

0.57

Haematologic parameters before COVID-19 infection

Median Hb, g/dL (range)

10.2 (6.3–14.7)

10.3 (7.8–14.7)

8.2 (6.3–12)

0.15

Median ANC, ×109/L (range)

3.4 (0.12–16.6)

2.93 (1.5–6.6)

7.7 (0.12–16.6)

0.06

Median ALC, ×109/L (range)

1.2 (0.4–4.0)

1.8 (0.4–4.0)

1.0 (0.68–2.8)

0.25

Median PLT, ×109/L (range)

166 (6–398)

166 (13–356)

107 (6–398)

0.8

Clinical features at COVID-19 infection

Symptoms at onset

Fever, n (%)

9 (56)

6 (55)

3 (60)

0.57

Cough, n (%)

6 (37.5)

5 (45)

1 (20)

0.43

Dyspnoea, n (%)

5 (31)

4 (36)

1 (20)

0.59

Diarrhoea, n (%)

2 (12.5)

2 (18)

0 (0)

0.66

Fatigue, n (%)

1 (6)

1 (9)

0 (0)

0.66

Asymptomatic, n (%)

2 (12.5)

1 (9)

1 (20)

0.57

Radiologic findings

n = 12

   

Unremarkable, n (%)

1 (8)

0 (0)

1 (20)

0.33

Monolateral focal lesions, n (%)

2 (17)

0 (0)

2 (40)

0.09

Bilateral focal lesions, n (%)

6 (50)

5 (40)

1 (20)

0.29

Interstitial pneumonia, n (%)

3 (25)

1 (10)

2 (40)

0.24

Associated pleural effusion, n (%)

1 (8)

0 (0)

1 (20)

0.33

Level of care

Hospital admission, n (%)

13 (80)

9 (82)

4 (80)

0.73

ICU admission, n (%)

2 (12,5)

1 (10)

1 (20)

0.57

Home quarantine, n (%)

3 (19)

2 (20)

1 (20)

0.75

Treatments

Oxygen, n (%)

12 (75)

7 (64)

5 (100)

0.15

NIV (CPAP included), n (%)

2 (12.5)

1 (9)

1 (20)

0.57

Steroids, n (%)

5 (31)

3 (27)

2 (40)

0.56

Heparin, n (%)

5 (31)

3 (27)

2 (40)

0.56

HCQ, n (%)

9 (56)

6 (55)

3 (60)

0.57

Antiviral, n (%)

3 (19)

3 (27)

0 (0)

0.42

Antibiotics, n (%)

9 (56)

6 (55)

3 (60)

0.7

Anti-IL6, n (%)

2 (12.5)

2 (18)

0 (0)

0.66

  1. All patients showed a positive nasopharyngeal swab.
  2. MDS myelodysplastic syndrome, MDS/MPN myelodysplastic/myeloproliferative syndrome, AML acute myelogenous leukaemia, CCI Charlson Comorbidity Index, ESA erythropoiesis stimulating agent, TKI tyrosine kinase inhibitos, BSC best supportive care, ACEi angiotensin converting enzyme inhibitor, ARBs angiotensin receptor blocker, Hb haemoglobin, ANC absolute neutrophil count, ALC absolute lymphocyte count, PLT platelets, ICU intensive care unit, NIV non-invasive ventilation, CPAP continuous positive airway pressure, HCQ hydroxychloroquine.
  3. Bold values indicate p values that are borderline for statistical significance and may suggest clinical meaningful differences.
Back to article page